The Rising Challenge of New Type Drugs and the Evolving Demand for Detection Solutions
February 10,2026
Over the past three years, as a manufacturer of in vitro diagnostic devices, we have continuously observed a significant shift in the landscape of illicit substances. Traditional drugs such as heroin, cocaine and amphetamines remain relevant. However, the market is increasingly being flooded by what are known as new psychoactive substances (NPS) -- chemically modified analogues of controlled drugs designed to circumvent legal regulation and standard detection methods.
These novel substances pose two major challenges for us as producers of detection devices. First, their high level of concealment: many are slight structural variations of known compounds (for example synthetic cannabinoids, synthetic cathinones and designer opioids) yet assume different physical forms (tablets, powders, herbal-type materials) and can evade conventional antibody-based immunoassays or fixed panel tests. Second, our customers - laboratories, occupational screening programmes and point-of-care systems -- are increasingly reporting failures in detecting these emerging compounds with traditional test panels. The implication is clear: conventional drug-of-abuse test devices that cover, say, 10 to 15 substances are no longer sufficient in the face of a rapidly evolving market.
From a production standpoint, we are seeing a clear trend: the demand is for broader-panel multiplex devices, expanded analytical coverage, and shorter turnaround time. Although publicly available data on the exact number of detection targets in each device remains limited, industry reports and regulatory surveillance reveal that over recent years agencies have recorded hundreds of new NPS types annually, forcing test manufacturers to raise the number of analytes covered. In response, we have accelerated R&D efforts: redesigning panels to include emerging synthetic opioids, designer stimulants and analogues of existing drugs; enhancing detection sensitivity; and adapting for point-of-care or workplace screening use.
In sum, from the manufacturer's perspective: new and hidden types of illicit substances are no longer fringe issues but core challenges. The phrase "more analytes, stronger detection, faster time-to-result" sums up the new demand. We remain committed to staying ahead of the curve - tracking regulatory developments, monitoring forensic trends and delivering detection solutions that meet the demands of this new era.
References:
1. Sajwani HS. The dilemma of new psychoactive substances: A growing threat. Saudi Pharmaceutical Journal. 2023;31:348-350. PMC
2. Santos IC, et al. New Psychoactive Substances: Health and Legal Challenges. Sustainability. 2024;3(2):18. MDPI
3. Lockhart ED, et al. New Psychoactive Substances (NPS) Trends in the United States. Trends in Analytical Chemistry. 2024. ScienceDirect
4. Krotulski AJ. Challenges in Identifying Novel Psychoactive Substances and a Stronger Path Forward. NIJ Notes from the Field. 2022. National Institute of JusticeEuropean Drug Report 2024: New psychoactive substances – the current situation in Europe. European Monitoring Centre for Drugs and Drug Addiction. 2024. euda.europa.eu